Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC

This article was originally published in The Tan Sheet

Executive Summary

Guidance document entitled "Class Labeling of OTC Topical Drug Products for the Treatment of Vaginal Yeast Infections (Vulvovaginal Candidiasis)" to be available from FDA "in the next several weeks" following a June 26 Federal Register notice announcing the topics of the July 28-29 meeting of NDAC. The guidance document also will be available on the Internet at www.fda.gov. The topics of the meeting include class labeling of vaginal yeast infection treatments (July 28) and performance expectations and final formulation testing requirements of OTC healthcare antiseptic drug products (July 29) ("The Tan Sheet" March 2, p. 5). The meeting will take place at the Holiday Inn in Bethesda, Md., beginning at 8:30 a.m. both days. The NDAC meeting scheduled to take place July 27 was canceled ("The Tan Sheet" June 8, In Brief)...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel